BOSTON and LAUSANNE, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) — SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today announced it will release its financial results for the second quarter of fiscal 2022 before U.S. markets open on Tuesday, August 9, 2022. SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:30 a.m. EDT / 2:30 p.m. CEST.
The call will be webcast live on the SOPHiA GENETICS Investor Relations website. Additionally, a replay will be available on the website after its completion.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by over 790 hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn and Instagram. Where others see data, we see answers.
Investor Contact:
Jennifer Pottage
Head of Investor Relations
[email protected]
Media Contact:
Don Granese
Public Relations
[email protected]
